(Q34291726)

1 August 2017

title

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation (English)

1 reference

1 August 2017

main subject

liver transplantation

1 reference

D Kaemmerer

1

1 reference

1 August 2017

B Schmidt

2

1 reference

1 August 2017

G Lehmann

3

1 reference

1 August 2017

G Wolf

4

1 reference

1 August 2017

M Hommann

5

1 reference

1 August 2017

U Settmacher

6

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Transplantation Proceedings

1 August 2017

published in

1 reference

1 August 2017

volume

44

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

1362-1367

1 reference

Post-liver transplantation osteoporosis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Osteoporosis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Effect of chronic glucocorticoid therapy and the gender difference on bone mineral density in liver transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Evaluation and management of bone disease and fractures post transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Incidence of vertebral fractures in the first three months after orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Bone mineral status in end-stage liver disease and the effect of liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Bone loss after orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Bone disorders in chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Effect of nutrition and body composition on bone density after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Effect of bisphosphonates on bone mineral density in liver transplant patients: a meta-analysis and systematic review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Calcitriol in prevention and therapy of osteoporosis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Treatment of osteoporosis after liver transplantation with ibandronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Steroid-free organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

AGA technical review on osteoporosis in hepatic disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Bone mineral density before and after OLT: long-term follow-up and predictive factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Approach to the patient with transplantation-related bone loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Management of bone loss after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.01.133

10.1016/J.TRANSPROCEED.2012.01.133

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference